July 31, 2023 Quanterix’s Simoa® Technology Powers Large, International Reference Range Study Utilizing Serum Neurofilament Light (sNfL) to Assess Neurological Disease Activity in Pediatric Patients read more
July 6, 2023 Quanterix Launches LucentAD Biomarker Blood Test to Aid Physician Diagnosis of Alzheimer’s Disease in Patients read more
June 7, 2023 Quanterix to Participate in Fireside Chat at Goldman Sachs Annual Global Healthcare Conference read more
April 25, 2023 FDA Accelerated Approval of Tofersen Highlights Importance of Blood Neurofilament Light Chain as Surrogate Endpoint in Neurology Therapeutic Trials read more